QNCX Quote, Financials, Valuation and Earnings

Gossamer Bio, Inc. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of -362.73%. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Gossamer Bio, Inc.'s return on equity of -615%.

Quince Therapeutics, Inc. has a consensus price target of $5.00, signalling downside risk potential of -100%. On the other hand Gossamer Bio, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 1238.13%. Given that Gossamer Bio, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Quince Therapeutics, Inc..

Quince Therapeutics, Inc. has a beta of 1.282, which suggesting that the stock is 28.179% more volatile than S&P 500. In comparison Gossamer Bio, Inc. has a beta of 2.084, suggesting its more volatile than the S&P 500 by 108.445%.

Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gossamer Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Gossamer Bio, Inc. pays out -- of its earnings as a dividend.

Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Gossamer Bio, Inc. quarterly revenues of $13.3M. Quince Therapeutics, Inc.'s net income of -$13.4M is higher than Gossamer Bio, Inc.'s net income of -$48.2M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Gossamer Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 2.19x for Gossamer Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of 15.01%. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Masimo Corp.'s return on equity of 22.71%.

Quince Therapeutics, Inc. has a consensus price target of $5.00, signalling downside risk potential of -100%. On the other hand Masimo Corp. has an analysts' consensus of $178.60 which suggests that it could grow by 1.85%. Given that Masimo Corp. has higher upside potential than Quince Therapeutics, Inc., analysts believe Masimo Corp. is more attractive than Quince Therapeutics, Inc..

Quince Therapeutics, Inc. has a beta of 1.282, which suggesting that the stock is 28.179% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.291%.

Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Masimo Corp. quarterly revenues of $412.5M. Quince Therapeutics, Inc.'s net income of -$13.4M is lower than Masimo Corp.'s net income of $61.9M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 6.18x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix, Inc. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of -487.96%. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Ocular Therapeutix, Inc.'s return on equity of -73.88%.

Quince Therapeutics, Inc. has a consensus price target of $5.00, signalling downside risk potential of -100%. On the other hand Ocular Therapeutix, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 187.1%. Given that Ocular Therapeutix, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Ocular Therapeutix, Inc. is more attractive than Quince Therapeutics, Inc..

Quince Therapeutics, Inc. has a beta of 1.282, which suggesting that the stock is 28.179% more volatile than S&P 500. In comparison Ocular Therapeutix, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.316%.

Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Ocular Therapeutix, Inc. pays out -- of its earnings as a dividend.

Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Ocular Therapeutix, Inc. quarterly revenues of $13.3M. Quince Therapeutics, Inc.'s net income of -$13.4M is higher than Ocular Therapeutix, Inc.'s net income of -$64.7M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Ocular Therapeutix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 32.22x for Ocular Therapeutix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of -304.24%. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

Quince Therapeutics, Inc. has a consensus price target of $5.00, signalling downside risk potential of -100%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 82.95%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Quince Therapeutics, Inc..

Quince Therapeutics, Inc. has a beta of 1.282, which suggesting that the stock is 28.179% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. Quince Therapeutics, Inc.'s net income of -$13.4M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 22.04x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.